158 related articles for article (PubMed ID: 9250313)
21. Use of CD34 and factor VIII to diagnose hepatocellular carcinoma on fine needle aspirates.
Gottschalk-Sabag S; Ron N; Glick T
Acta Cytol; 1998; 42(3):691-6. PubMed ID: 9622689
[TBL] [Abstract][Full Text] [Related]
22. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel.
Saleh HA; Aulicino M; Zaidi SY; Khan AZ; Masood S
Diagn Cytopathol; 2009 Mar; 37(3):184-90. PubMed ID: 19170172
[TBL] [Abstract][Full Text] [Related]
23. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
24. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
25. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
[TBL] [Abstract][Full Text] [Related]
26. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections.
Balaton AJ; Nehama-Sibony M; Gotheil C; Callard P; Baviera EE
J Pathol; 1988 Dec; 156(4):305-10. PubMed ID: 2465399
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration.
Zimmerman RL; Burke M; Young NA; Solomides CC; Bibbo M
Cancer; 2002 Feb; 96(1):53-7. PubMed ID: 11836704
[TBL] [Abstract][Full Text] [Related]
28. Cytomorphology of combined hepatocellular-cholangiocarcinoma in fine needle aspirates of the liver. A report of two cases.
Kilpatrick SE; Geisinger KR; Loggie BW; Hopkins MB
Acta Cytol; 1993; 37(6):943-7. PubMed ID: 7504382
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma with mesothelioma-like dissemination.
Otsuki Y; Shimizu S; Hosoda Y; Nagasawa M; Sato Y; Kobayashi H
Pathol Int; 2005 Nov; 55(11):738-44. PubMed ID: 16271087
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of CD10 immunohistochemical staining on cellblock in differentiating hepatocellular carcinoma from secondary malignancies of liver.
Singha J; Khan K; Chatterjee S
Indian J Pathol Microbiol; 2018; 61(4):510-515. PubMed ID: 30303139
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of primary and metastatic clear cell tumors in the liver by in situ hybridization for albumin messenger RNA.
Oliveira AM; Erickson LA; Burgart LJ; Lloyd RV
Am J Surg Pathol; 2000 Feb; 24(2):177-82. PubMed ID: 10680884
[TBL] [Abstract][Full Text] [Related]
32. Fine needle aspiration biopsy of hepatocellular carcinoma. Value of immunocytochemical and ultrastructural studies.
Guindi M; Yazdi HM; Gilliatt MA
Acta Cytol; 1994; 38(3):385-91. PubMed ID: 7514832
[TBL] [Abstract][Full Text] [Related]
33. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
Morrison C; Marsh W; Frankel WL
Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
[TBL] [Abstract][Full Text] [Related]
34. Cytodiagnosis of hepatocellular carcinoma in fine-needle aspirates of the liver: its differentiation from reactive hepatocytes and metastatic adenocarcinoma.
Das DK
Diagn Cytopathol; 1999 Dec; 21(6):370-7. PubMed ID: 10572267
[TBL] [Abstract][Full Text] [Related]
35. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors.
Minervini MI; Demetris AJ; Lee RG; Carr BI; Madariaga J; Nalesnik MA
Mod Pathol; 1997 Jul; 10(7):686-92. PubMed ID: 9237179
[TBL] [Abstract][Full Text] [Related]
36. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
[TBL] [Abstract][Full Text] [Related]
37. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
[TBL] [Abstract][Full Text] [Related]
38. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples.
Siddiqui MT; Saboorian MH; Gokaslan ST; Ashfaq R
Cancer; 2002 Feb; 96(1):49-52. PubMed ID: 11836703
[TBL] [Abstract][Full Text] [Related]
40. [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers].
Pozharisskiĭ KM; Granov DA; Ten VP; Kubaĭbergenova AG; Leenman EE; Rasskazov AI
Vopr Onkol; 2008; 54(4):417-33. PubMed ID: 18942395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
